Concord Biotech Limited (NSE:CONCORDBIO)

Revenue by Segment

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
Manufacturing and trading in pharmaceutical products	10.55B	12.00B	10.17B	8.53B	7.13B
Total	10.55B	12.00B	10.17B	8.53B	7.13B

Revenue by Geography

Financials in millions INR. Fiscal year is April - March.

Fiscal Year	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021	Mar 31, 2020
India	5.64B	6.62B	5.34B	4.32B	3.39B
America	1.08B	1.38B	1.08B	1.47B	1.31B
Others	3.83B	4.00B	3.75B	2.74B	2.42B
Total	10.55B	12.00B	10.17B	8.53B	7.13B

Data Source: S&P Global Market Intelligence Last updated: Jul 31, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Sep 11, 2026

Data Sources Report a data error